Nebulized AER101 in Pre-op NSCLC

ClinicalTrials.gov ID

NCT07631299

Lead Sponsor

University of OklahomaOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Early Phase 1

Enrollment

5Estimated

Last Update Posted

Jun 8, 2026Actual

Start Date

Jun 2026Estimated

Primary Completion Date

Dec 2026Estimated

Completion Date

Jun 2027Estimated

Official Title

Nebulized AER101 to Inhibit Glycolysis for Pre-Operative Non-small Cell Lung Cancer (NSCLC)

Brief Summary

The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC). Glycolysis is the process cells use to break down sugar (glucose) into a smaller substance in the fluid part inside the cell. Many lung cancers begin in bronchi, bronchioles and alveoli cells surrounding the airways, which enables nebulization to deposit AER101 on lung tumors.

Participants in the study will self-administer AER101 via a hand-held personal nebulizer three times per day (dosing at least 4 hours apart) for 14 days prior to undergoing surgery for lung cancer.

Detailed Description

This is a pilot study that will enroll 5 patients with Stage I or Stage II NSCLC. Each patient will receive a nebulizer and will self-administer the study drug 3 times a day for 14 days. The research team will perform a PET CT scan at the beginning of the study (no more than 30 days prior to study) and again at the last treatment. The final treatment will be done at the clinic so that the PET/CT can be performed within about one hour. Patient surgery will already be scheduled to occur shortly after the treatment has been completed.

Patients will also complete a daily assessment survey at each treatment time.

There is only one treatment arm and no control group.

The study is of minimal risk and the investigator expects enrollment to be completed in approximately 6 months.

• Non-small Cell Lung Cancer Stage I
• Non-small Cell Lung Cancer Stage II

• AER101

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• 18 years or older
• Agree to sign consent and follow study requirements
• Recently diagnosed with lung adenocarcinoma or squamous cell carcinoma
• Primary patients prior to resection
• Candidate for surgery (patients are qualified for inclusion if surgery or radiation treatment are agreed to)
• Baseline PET/CT imaging performed at Stephenson Cancer Center available and performed within previous 30 days

Exclusion Criteria:

• Recurrent tumor(s)
• Nodal or metastatic tumor (multiple lung tumors are acceptable)
• Pregnant patients
• Patients unable to provide informed consent
• Prisoners

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

University of OklahomaOTHER

theresa-lander@ou.edu4054015633

• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT06694454

  SuspendedInterventionalPhase 1Phase 2Updated Sep 11, 2026
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  NCT07489066

  RecruitingInterventionalPhase 2Updated Aug 17, 2026
• Perioperative Immunotherapy for NSCLC (ECTOP-1030)

  NCT06572722

  WithdrawnInterventionalPhase 2Updated Apr 27, 2026
• NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

  NCT07318636

  Not yet recruitingInterventionalPhase 1Updated Jan 6, 2026
• Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

  NCT00988169

  TerminatedInterventionalPhase 2Updated Nov 20, 2015
• A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

  NCT02276027

  CompletedInterventionalPhase 2Updated Dec 16, 2020